Stock HUMAN GENOME SCIENCES
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Human Genome Sciences

Equities

US4449031081

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Human Genome Sciences
2012 Actelion Ltd : Exclusive: Human Genome rejected Amgen's $7 billion bid in 2010: sources RE
2012 BioMarin Pharmaceutical Inc. : GSK clinches deal to buy Human Genome for $3 billion RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Human Genome Sciences : ANNOUNCES REQUIRED OFFER TO REPURCHASE IN RESPECT OF ITS 3.00% CONVERTIBLE SENIOR NOTES DUE 2018
PU
Human Genome Sciences : Securities Lawyers at Goldfarb LLP Seeking More Money, Information for Stockholders of Human Genome Sciences, Inc.
PR
Human Genome Sciences : Law Offices of Howard G. Smith Announces Investigation of Human Genome Sciences Inc. Board of Directors for Potential Breaches of Fiduciary Duty
BU
Human Genome Sciences : Law Office of Brodsky & Smith, LLC Announces Investigation of Human Genome Sciences, Inc.
PR
Human Genome Sciences : Ryan & Maniskas, LLP Announces Investigation of Human Genome Sciences Inc.
BU
Human Genome Sciences : GSK to acquire Human Genome Sciences for US$14.25 per share in cash
BU
Human Genome Sciences : FYI From Human Genome Sciences: GlaxoSmithKline Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes
BU
Human Genome Sciences : Announces Resubmission of Raxibacumab BLA to FDA
BU
Human Genome Sciences : Responds To GSK Extension of Unsolicited Tender Offer
BU
Human Genome Sciences : REPEAT/Human Genome Sciences Announces July 16 as the Date for Submission of Definitive Acquisition Proposals
BU
Human Genome Sciences : Announces July 16 as the Date for Submission of Definitive Acquisition Proposals
BU
Human Genome Sciences : FYI from Human Genome Sciences: GlaxoSmithKline Announces New Data from Phase 3 Studies of Once-Weekly Albiglutide in Type 2 Diabetes
BU
Human Genome Sciences : Responds to GSK Extension of Unsolicited Tender Offer
BU
Human Genome Sciences : Announces Multiple Abstracts Related to BENLYSTA® and Systemic Lupus Erythematosus to Be Presented at the 2012 EULAR Annual European Congress of Rheumatology
BU
Human Genome Sciences : Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference
BU
Human Genome Sciences : Response to GSK Press Release
BU
Human Genome Sciences : ANNOUNCES ADOPTION OF SHORT-TERM STOCKHOLDER RIGHTS PLAN
PU
Human Genome Sciences : Board of Directors Unanimously Determines GlaxoSmithKline Unsolicited Tender Offer is Inadequate and Not in the Best Interests of Stockholders
BU
Human Genome Sciences : Board of Directors to Review Unsolicited Tender Offer From GlaxoSmithKline
BU
Human Genome Sciences : Announces First Quarter 2012 Financial Results
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Human Genome Sciences
  5. Press Releases